ACHN News and Press, Achison Inc Cl A From 10/23/19

NEW YORK, NY / ACCESSWIRE / October 23, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Achillion Pharmaceuticals, Inc (NASDAQ: ACHN ...

Market Pulse Biotech and pharmaceutical groups have struggled immensely over the past two months as unique issues affecting the industry have become more dominant. The general market skittishness over rate policy and tariffs have also contributed to the woes. However, with the broader mark...

Wednesday was a downbeat day on Wall Street, as investors continued to waver in their confidence about the likely direction of trade negotiations between the U.S. and China. After feeling more optimistic earlier in the week, market participants focused on some of the potential problems if trade ...

ACHN stock has gained 70% today after it was announced that Alexion Pharmaceuticals (NASDAQ:ALXN) would acquire Achillion Pharmaceuticals (NASDAQ:ACHN) in a deal worth $930 million USD. Alexion to Pay 73% Premium on ACHN Stock In a move that will allow Alexion to consolidate its st...

Gainers:  Viveve Medical (NASDAQ: VIVE ) +91% . Achillion Pharmaceuticals (NASDAQ: ACHN ) +71% . Regional Health Properties (NYSEMKT: RHE ) +53% . Xenetic Biosciences (NASDAQ: XBIO ) +44% . Assembly Biosciences (NASDAQ: ASMB ) +30% . Ideal Power (NASDAQ: IPWR ) +29% . Aethlon Me...

NEW YORK, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) to Alexion Pharmaceuticals, Inc. (“Alexion”) is fair to Achillion shareholders. On behalf of Ach...

Viveve Medical (NASDAQ: VIVE ) +109%  on robust volume on no particular news. More news on: Viveve Medical, Inc., Achillion Pharmaceuticals, Inc., Ideal Power Inc., Stocks on the move, Read more ...

Alexion Pharmaceuticals (NASDAQ: ALXN ) has agreed to acquire Achillion Pharmaceuticals (NASDAQ: ACHN ) for $6.30 per share in cash for a total of ~$930M, including Achillion's cash on hand of ~$230M. More news on: Alexion Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., Healthcar...

- Adds clinical-stage portfolio of oral small molecule Factor D inhibitors to Alexion’s pipeline - - Provides opportunity to enhance treatment for PNH patients experiencing extravascular hemolysis (EVH), potential first-in-class C3 glomerulopathy (C3G) therapy & promising de...

Achillion Pharmaceuticals (ACHN) had received Breakthrough Therapy Designation from the FDA for its drug danicopan for the treatment of paroxysmal nocturnal hemoglobinuria ((PNH)). This indication was given because of positive preliminary data, from a phase 2 study, that was released sever...